This week on Pharm5:

  • New COVID booster recommendations
  • Transdermal dextroamphetamine for ADHD
  • No ivermectin for COVID-19
  • North Carolina’s workplace condition complaint form
  • ASHP Phase II rank list due Wednesday, April 6th

Connect with us!

  • Listen to our podcast: Pharm5
  • Watch us on TikTok: @LizHearnPharmD
  • Follow us on Twitter: @LizHearnPharmD

References:

  1. CDC recommends additional boosters for certain individuals. Centers for Disease Control and Prevention. https://www.cdc.gov/media/releases/2022/s0328-covid-19-boosters.html. Published March 29, 2022. Accessed March 31, 2022.
  2. Pfizer and BioNTech submit for U.S. emergency use authorization of an additional booster dose of their COVID-19 vaccine for older adults. Pfizer. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-submit-us-emergency-use-authorization. Published March 15, 2022. Accessed March 16, 2022.
  3. FDA Approves Xelstrym.https://www.drugs.com/newdrugs/fda-approves-xelstrym-dextroamphetamine-transdermal-attention-deficit-hyperactivity-disorder-adhd-5805.html. Published March 23, 2022. Accessed March 23, 2022.
  4. Reis G, Silva EASM, Silva DCM, et al. Effect of early treatment with ivermectin among patients with covid-19. New England Journal of Medicine. 2022. doi:10.1056/nejmoa2115869
  5. Working Conditions Complaint Form. http://www.ncbop.org/NewsItems/WorkingConditionsComplaintForm.html. Accessed March 31, 2022.
  6. Schedule of dates. ASHP Match | Schedule. https://natmatch.com/ashprmp/schedule.html. Published January 6, 2022. Accessed March 16, 2022.

See All 59 Episodes of "Pharm5"